2023
Saenger, Jonathan A; Tahir, Ismail; Födinger, Manuela; Cote, Gregory M; Muniappan, Ashok; Fintelmann, Florian J
2023, ISSN: 1930-0433.
@misc{pmid37577077,
title = {Multimodality local ablative therapy of 23 lung metastases with surgical resection and percutaneous cryoablation in a patient with Li-Fraumeni Syndrome: A case report},
author = {Jonathan A Saenger and Ismail Tahir and Manuela Födinger and Gregory M Cote and Ashok Muniappan and Florian J Fintelmann},
doi = {10.1016/j.radcr.2023.07.047},
issn = {1930-0433},
year = {2023},
date = {2023-10-01},
journal = {Radiol Case Rep},
volume = {18},
number = {10},
pages = {3586--3591},
abstract = {Patients with Li-Fraumeni syndrome (LFS) are prone to develop a variety of malignancies due to insufficient activity of the encoded tumor suppressor protein P53, including adrenocortical carcinoma, breast cancer, lung cancer, pancreatic cancer, and sarcoma. In the setting of LFS, local treatment options for lung metastases are limited to surgery and thermal ablation since radiotherapy and some systemic therapies predispose patients to additional future malignancies. We present the case of a 45-year-old woman with LFS with leiomyosarcoma metastases to both lungs who underwent bilateral wedge resections to treat a total of eight lung metastases followed by six percutaneous cryoablation sessions to treat 15 additional lung metastases over a period of 24 months. Our case demonstrates the option of multimodal local ablative therapies for lung metastases in patients with LFS, including percutaneous cryoablation.},
keywords = {},
pubstate = {published},
tppubtype = {misc}
}
Patients with Li-Fraumeni syndrome (LFS) are prone to develop a variety of malignancies due to insufficient activity of the encoded tumor suppressor protein P53, including adrenocortical carcinoma, breast cancer, lung cancer, pancreatic cancer, and sarcoma. In the setting of LFS, local treatment options for lung metastases are limited to surgery and thermal ablation since radiotherapy and some systemic therapies predispose patients to additional future malignancies. We present the case of a 45-year-old woman with LFS with leiomyosarcoma metastases to both lungs who underwent bilateral wedge resections to treat a total of eight lung metastases followed by six percutaneous cryoablation sessions to treat 15 additional lung metastases over a period of 24 months. Our case demonstrates the option of multimodal local ablative therapies for lung metastases in patients with LFS, including percutaneous cryoablation.
Saenger, Jonathan A; Tahir, Ismail; Födinger, Manuela; Cote, Gregory M; Muniappan, Ashok; Fintelmann, Florian J
2023, ISSN: 1930-0433.
@misc{pmid37577077b,
title = {Multimodality local ablative therapy of 23 lung metastases with surgical resection and percutaneous cryoablation in a patient with Li-Fraumeni Syndrome: A case report},
author = {Jonathan A Saenger and Ismail Tahir and Manuela Födinger and Gregory M Cote and Ashok Muniappan and Florian J Fintelmann},
doi = {10.1016/j.radcr.2023.07.047},
issn = {1930-0433},
year = {2023},
date = {2023-10-01},
journal = {Radiol Case Rep},
volume = {18},
number = {10},
pages = {3586--3591},
abstract = {Patients with Li-Fraumeni syndrome (LFS) are prone to develop a variety of malignancies due to insufficient activity of the encoded tumor suppressor protein P53, including adrenocortical carcinoma, breast cancer, lung cancer, pancreatic cancer, and sarcoma. In the setting of LFS, local treatment options for lung metastases are limited to surgery and thermal ablation since radiotherapy and some systemic therapies predispose patients to additional future malignancies. We present the case of a 45-year-old woman with LFS with leiomyosarcoma metastases to both lungs who underwent bilateral wedge resections to treat a total of eight lung metastases followed by six percutaneous cryoablation sessions to treat 15 additional lung metastases over a period of 24 months. Our case demonstrates the option of multimodal local ablative therapies for lung metastases in patients with LFS, including percutaneous cryoablation.},
keywords = {},
pubstate = {published},
tppubtype = {misc}
}
Patients with Li-Fraumeni syndrome (LFS) are prone to develop a variety of malignancies due to insufficient activity of the encoded tumor suppressor protein P53, including adrenocortical carcinoma, breast cancer, lung cancer, pancreatic cancer, and sarcoma. In the setting of LFS, local treatment options for lung metastases are limited to surgery and thermal ablation since radiotherapy and some systemic therapies predispose patients to additional future malignancies. We present the case of a 45-year-old woman with LFS with leiomyosarcoma metastases to both lungs who underwent bilateral wedge resections to treat a total of eight lung metastases followed by six percutaneous cryoablation sessions to treat 15 additional lung metastases over a period of 24 months. Our case demonstrates the option of multimodal local ablative therapies for lung metastases in patients with LFS, including percutaneous cryoablation.
Saenger, Jonathan A; Tahir, Ismail; Födinger, Manuela; Cote, Gregory M; Muniappan, Ashok; Fintelmann, Florian J
2023, ISSN: 1930-0433.
@misc{pmid37577077c,
title = {Multimodality local ablative therapy of 23 lung metastases with surgical resection and percutaneous cryoablation in a patient with Li-Fraumeni Syndrome: A case report},
author = {Jonathan A Saenger and Ismail Tahir and Manuela Födinger and Gregory M Cote and Ashok Muniappan and Florian J Fintelmann},
doi = {10.1016/j.radcr.2023.07.047},
issn = {1930-0433},
year = {2023},
date = {2023-10-01},
journal = {Radiol Case Rep},
volume = {18},
number = {10},
pages = {3586--3591},
abstract = {Patients with Li-Fraumeni syndrome (LFS) are prone to develop a variety of malignancies due to insufficient activity of the encoded tumor suppressor protein P53, including adrenocortical carcinoma, breast cancer, lung cancer, pancreatic cancer, and sarcoma. In the setting of LFS, local treatment options for lung metastases are limited to surgery and thermal ablation since radiotherapy and some systemic therapies predispose patients to additional future malignancies. We present the case of a 45-year-old woman with LFS with leiomyosarcoma metastases to both lungs who underwent bilateral wedge resections to treat a total of eight lung metastases followed by six percutaneous cryoablation sessions to treat 15 additional lung metastases over a period of 24 months. Our case demonstrates the option of multimodal local ablative therapies for lung metastases in patients with LFS, including percutaneous cryoablation.},
keywords = {},
pubstate = {published},
tppubtype = {misc}
}
Patients with Li-Fraumeni syndrome (LFS) are prone to develop a variety of malignancies due to insufficient activity of the encoded tumor suppressor protein P53, including adrenocortical carcinoma, breast cancer, lung cancer, pancreatic cancer, and sarcoma. In the setting of LFS, local treatment options for lung metastases are limited to surgery and thermal ablation since radiotherapy and some systemic therapies predispose patients to additional future malignancies. We present the case of a 45-year-old woman with LFS with leiomyosarcoma metastases to both lungs who underwent bilateral wedge resections to treat a total of eight lung metastases followed by six percutaneous cryoablation sessions to treat 15 additional lung metastases over a period of 24 months. Our case demonstrates the option of multimodal local ablative therapies for lung metastases in patients with LFS, including percutaneous cryoablation.
Saraf, Anurag; Tahir, Ismail; Hu, Bonnie; Dietrich, Anna-Sophia W; Tonnesen, P Erik; Sharp, Gregory C; Tillman, Gayle; Roeland, Eric J; Nipp, Ryan D; Comander, Amy; Peppercorn, Jeffery; Fintelmann, Florian J; Jimenez, Rachel B
In: Int J Radiat Oncol Biol Phys, 2023, ISSN: 1879-355X.
@article{pmid37506979,
title = {Association of Sarcopenia With Toxicity-Related Discontinuation of Adjuvant Endocrine Therapy in Women With Early-Stage Hormone Receptor-Positive Breast Cancer},
author = {Anurag Saraf and Ismail Tahir and Bonnie Hu and Anna-Sophia W Dietrich and P Erik Tonnesen and Gregory C Sharp and Gayle Tillman and Eric J Roeland and Ryan D Nipp and Amy Comander and Jeffery Peppercorn and Florian J Fintelmann and Rachel B Jimenez},
doi = {10.1016/j.ijrobp.2023.07.018},
issn = {1879-355X},
year = {2023},
date = {2023-07-01},
journal = {Int J Radiat Oncol Biol Phys},
abstract = {PURPOSE: Sarcopenia, an age-related decline in muscle mass and physical function, is associated with increased toxicity and worse outcomes in women with breast cancer (BC). Sarcopenia may contribute to toxicity-related early discontinuation of adjuvant endocrine therapy (aET) in women with hormone receptor-positive (HR+) BC but remains poorly characterized.nnMETHODS AND MATERIALS: This multicenter, retrospective cohort study included consecutive women with stage 0-II HR+ BC who received breast conserving therapy (lumpectomy and radiation therapy) and aET from 2011 to 2017 with a 5-year follow-up. Skeletal muscle index (SMI, cm/m) was analyzed using a deep learning model on routine cross-sectional radiation simulation imaging; sarcopenia was dichotomized according to previously validated reports. The primary endpoint was toxicity-related aET discontinuation; logistic regression analysis evaluated associations between SMI/sarcopenia and aET discontinuation. Cox regression analysis evaluated associations with time to aET toxicity, ipsilateral breast tumor recurrence (IBTR), and disease-free survival (DFS).nnRESULTS: A total of 305 women (median follow-up, 89 months) were included with a median age of 67 years and early-stage BC (12% stage 0, 65% stage I). A total of 60 (20%) women experienced toxicity-related aET discontinuation. Sarcopenia was associated with toxicity-related early discontinuation of aET (odds ratio, 2.18; P = .036) and shorter time to aET toxicity (hazard ratio [HR], 1.62; P = .031). SMI or sarcopenia were not independently associated with IBTR or DFS; toxicity-related aET discontinuation was associated with worse IBTR (HR, 9.47; P = .002) and worse DFS (HR, 4.53; P = .001).nnCONCLUSIONS: Among women with early-stage HR+ BC who receive adjuvant radiation therapy and hormone therapy, sarcopenia is associated with toxicity-related early discontinuation of aET. Further studies should validate these findings in women who did not receive adjuvant radiation therapy. These high-risk patients may be candidates for aggressive symptom management and/or alternative treatment strategies to improve outcomes.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
PURPOSE: Sarcopenia, an age-related decline in muscle mass and physical function, is associated with increased toxicity and worse outcomes in women with breast cancer (BC). Sarcopenia may contribute to toxicity-related early discontinuation of adjuvant endocrine therapy (aET) in women with hormone receptor-positive (HR+) BC but remains poorly characterized.nnMETHODS AND MATERIALS: This multicenter, retrospective cohort study included consecutive women with stage 0-II HR+ BC who received breast conserving therapy (lumpectomy and radiation therapy) and aET from 2011 to 2017 with a 5-year follow-up. Skeletal muscle index (SMI, cm/m) was analyzed using a deep learning model on routine cross-sectional radiation simulation imaging; sarcopenia was dichotomized according to previously validated reports. The primary endpoint was toxicity-related aET discontinuation; logistic regression analysis evaluated associations between SMI/sarcopenia and aET discontinuation. Cox regression analysis evaluated associations with time to aET toxicity, ipsilateral breast tumor recurrence (IBTR), and disease-free survival (DFS).nnRESULTS: A total of 305 women (median follow-up, 89 months) were included with a median age of 67 years and early-stage BC (12% stage 0, 65% stage I). A total of 60 (20%) women experienced toxicity-related aET discontinuation. Sarcopenia was associated with toxicity-related early discontinuation of aET (odds ratio, 2.18; P = .036) and shorter time to aET toxicity (hazard ratio [HR], 1.62; P = .031). SMI or sarcopenia were not independently associated with IBTR or DFS; toxicity-related aET discontinuation was associated with worse IBTR (HR, 9.47; P = .002) and worse DFS (HR, 4.53; P = .001).nnCONCLUSIONS: Among women with early-stage HR+ BC who receive adjuvant radiation therapy and hormone therapy, sarcopenia is associated with toxicity-related early discontinuation of aET. Further studies should validate these findings in women who did not receive adjuvant radiation therapy. These high-risk patients may be candidates for aggressive symptom management and/or alternative treatment strategies to improve outcomes.
Saraf, Anurag; Tahir, Ismail; Hu, Bonnie; Dietrich, Anna-Sophia W; Tonnesen, P Erik; Sharp, Gregory C; Tillman, Gayle; Roeland, Eric J; Nipp, Ryan D; Comander, Amy; Peppercorn, Jeffery; Fintelmann, Florian J; Jimenez, Rachel B
In: Int J Radiat Oncol Biol Phys, 2023, ISSN: 1879-355X.
@article{pmid37506979b,
title = {Association of Sarcopenia With Toxicity-Related Discontinuation of Adjuvant Endocrine Therapy in Women With Early-Stage Hormone Receptor-Positive Breast Cancer},
author = {Anurag Saraf and Ismail Tahir and Bonnie Hu and Anna-Sophia W Dietrich and P Erik Tonnesen and Gregory C Sharp and Gayle Tillman and Eric J Roeland and Ryan D Nipp and Amy Comander and Jeffery Peppercorn and Florian J Fintelmann and Rachel B Jimenez},
doi = {10.1016/j.ijrobp.2023.07.018},
issn = {1879-355X},
year = {2023},
date = {2023-07-01},
journal = {Int J Radiat Oncol Biol Phys},
abstract = {PURPOSE: Sarcopenia, an age-related decline in muscle mass and physical function, is associated with increased toxicity and worse outcomes in women with breast cancer (BC). Sarcopenia may contribute to toxicity-related early discontinuation of adjuvant endocrine therapy (aET) in women with hormone receptor-positive (HR+) BC but remains poorly characterized.nnMETHODS AND MATERIALS: This multicenter, retrospective cohort study included consecutive women with stage 0-II HR+ BC who received breast conserving therapy (lumpectomy and radiation therapy) and aET from 2011 to 2017 with a 5-year follow-up. Skeletal muscle index (SMI, cm/m) was analyzed using a deep learning model on routine cross-sectional radiation simulation imaging; sarcopenia was dichotomized according to previously validated reports. The primary endpoint was toxicity-related aET discontinuation; logistic regression analysis evaluated associations between SMI/sarcopenia and aET discontinuation. Cox regression analysis evaluated associations with time to aET toxicity, ipsilateral breast tumor recurrence (IBTR), and disease-free survival (DFS).nnRESULTS: A total of 305 women (median follow-up, 89 months) were included with a median age of 67 years and early-stage BC (12% stage 0, 65% stage I). A total of 60 (20%) women experienced toxicity-related aET discontinuation. Sarcopenia was associated with toxicity-related early discontinuation of aET (odds ratio, 2.18; P = .036) and shorter time to aET toxicity (hazard ratio [HR], 1.62; P = .031). SMI or sarcopenia were not independently associated with IBTR or DFS; toxicity-related aET discontinuation was associated with worse IBTR (HR, 9.47; P = .002) and worse DFS (HR, 4.53; P = .001).nnCONCLUSIONS: Among women with early-stage HR+ BC who receive adjuvant radiation therapy and hormone therapy, sarcopenia is associated with toxicity-related early discontinuation of aET. Further studies should validate these findings in women who did not receive adjuvant radiation therapy. These high-risk patients may be candidates for aggressive symptom management and/or alternative treatment strategies to improve outcomes.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
PURPOSE: Sarcopenia, an age-related decline in muscle mass and physical function, is associated with increased toxicity and worse outcomes in women with breast cancer (BC). Sarcopenia may contribute to toxicity-related early discontinuation of adjuvant endocrine therapy (aET) in women with hormone receptor-positive (HR+) BC but remains poorly characterized.nnMETHODS AND MATERIALS: This multicenter, retrospective cohort study included consecutive women with stage 0-II HR+ BC who received breast conserving therapy (lumpectomy and radiation therapy) and aET from 2011 to 2017 with a 5-year follow-up. Skeletal muscle index (SMI, cm/m) was analyzed using a deep learning model on routine cross-sectional radiation simulation imaging; sarcopenia was dichotomized according to previously validated reports. The primary endpoint was toxicity-related aET discontinuation; logistic regression analysis evaluated associations between SMI/sarcopenia and aET discontinuation. Cox regression analysis evaluated associations with time to aET toxicity, ipsilateral breast tumor recurrence (IBTR), and disease-free survival (DFS).nnRESULTS: A total of 305 women (median follow-up, 89 months) were included with a median age of 67 years and early-stage BC (12% stage 0, 65% stage I). A total of 60 (20%) women experienced toxicity-related aET discontinuation. Sarcopenia was associated with toxicity-related early discontinuation of aET (odds ratio, 2.18; P = .036) and shorter time to aET toxicity (hazard ratio [HR], 1.62; P = .031). SMI or sarcopenia were not independently associated with IBTR or DFS; toxicity-related aET discontinuation was associated with worse IBTR (HR, 9.47; P = .002) and worse DFS (HR, 4.53; P = .001).nnCONCLUSIONS: Among women with early-stage HR+ BC who receive adjuvant radiation therapy and hormone therapy, sarcopenia is associated with toxicity-related early discontinuation of aET. Further studies should validate these findings in women who did not receive adjuvant radiation therapy. These high-risk patients may be candidates for aggressive symptom management and/or alternative treatment strategies to improve outcomes.
Saraf, Anurag; Tahir, Ismail; Hu, Bonnie; Dietrich, Anna-Sophia W; Tonnesen, P Erik; Sharp, Gregory C; Tillman, Gayle; Roeland, Eric J; Nipp, Ryan D; Comander, Amy; Peppercorn, Jeffery; Fintelmann, Florian J; Jimenez, Rachel B
In: Int J Radiat Oncol Biol Phys, 2023, ISSN: 1879-355X.
@article{pmid37506979c,
title = {Association of Sarcopenia With Toxicity-Related Discontinuation of Adjuvant Endocrine Therapy in Women With Early-Stage Hormone Receptor-Positive Breast Cancer},
author = {Anurag Saraf and Ismail Tahir and Bonnie Hu and Anna-Sophia W Dietrich and P Erik Tonnesen and Gregory C Sharp and Gayle Tillman and Eric J Roeland and Ryan D Nipp and Amy Comander and Jeffery Peppercorn and Florian J Fintelmann and Rachel B Jimenez},
doi = {10.1016/j.ijrobp.2023.07.018},
issn = {1879-355X},
year = {2023},
date = {2023-07-01},
journal = {Int J Radiat Oncol Biol Phys},
abstract = {PURPOSE: Sarcopenia, an age-related decline in muscle mass and physical function, is associated with increased toxicity and worse outcomes in women with breast cancer (BC). Sarcopenia may contribute to toxicity-related early discontinuation of adjuvant endocrine therapy (aET) in women with hormone receptor-positive (HR+) BC but remains poorly characterized.nnMETHODS AND MATERIALS: This multicenter, retrospective cohort study included consecutive women with stage 0-II HR+ BC who received breast conserving therapy (lumpectomy and radiation therapy) and aET from 2011 to 2017 with a 5-year follow-up. Skeletal muscle index (SMI, cm/m) was analyzed using a deep learning model on routine cross-sectional radiation simulation imaging; sarcopenia was dichotomized according to previously validated reports. The primary endpoint was toxicity-related aET discontinuation; logistic regression analysis evaluated associations between SMI/sarcopenia and aET discontinuation. Cox regression analysis evaluated associations with time to aET toxicity, ipsilateral breast tumor recurrence (IBTR), and disease-free survival (DFS).nnRESULTS: A total of 305 women (median follow-up, 89 months) were included with a median age of 67 years and early-stage BC (12% stage 0, 65% stage I). A total of 60 (20%) women experienced toxicity-related aET discontinuation. Sarcopenia was associated with toxicity-related early discontinuation of aET (odds ratio, 2.18; P = .036) and shorter time to aET toxicity (hazard ratio [HR], 1.62; P = .031). SMI or sarcopenia were not independently associated with IBTR or DFS; toxicity-related aET discontinuation was associated with worse IBTR (HR, 9.47; P = .002) and worse DFS (HR, 4.53; P = .001).nnCONCLUSIONS: Among women with early-stage HR+ BC who receive adjuvant radiation therapy and hormone therapy, sarcopenia is associated with toxicity-related early discontinuation of aET. Further studies should validate these findings in women who did not receive adjuvant radiation therapy. These high-risk patients may be candidates for aggressive symptom management and/or alternative treatment strategies to improve outcomes.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
PURPOSE: Sarcopenia, an age-related decline in muscle mass and physical function, is associated with increased toxicity and worse outcomes in women with breast cancer (BC). Sarcopenia may contribute to toxicity-related early discontinuation of adjuvant endocrine therapy (aET) in women with hormone receptor-positive (HR+) BC but remains poorly characterized.nnMETHODS AND MATERIALS: This multicenter, retrospective cohort study included consecutive women with stage 0-II HR+ BC who received breast conserving therapy (lumpectomy and radiation therapy) and aET from 2011 to 2017 with a 5-year follow-up. Skeletal muscle index (SMI, cm/m) was analyzed using a deep learning model on routine cross-sectional radiation simulation imaging; sarcopenia was dichotomized according to previously validated reports. The primary endpoint was toxicity-related aET discontinuation; logistic regression analysis evaluated associations between SMI/sarcopenia and aET discontinuation. Cox regression analysis evaluated associations with time to aET toxicity, ipsilateral breast tumor recurrence (IBTR), and disease-free survival (DFS).nnRESULTS: A total of 305 women (median follow-up, 89 months) were included with a median age of 67 years and early-stage BC (12% stage 0, 65% stage I). A total of 60 (20%) women experienced toxicity-related aET discontinuation. Sarcopenia was associated with toxicity-related early discontinuation of aET (odds ratio, 2.18; P = .036) and shorter time to aET toxicity (hazard ratio [HR], 1.62; P = .031). SMI or sarcopenia were not independently associated with IBTR or DFS; toxicity-related aET discontinuation was associated with worse IBTR (HR, 9.47; P = .002) and worse DFS (HR, 4.53; P = .001).nnCONCLUSIONS: Among women with early-stage HR+ BC who receive adjuvant radiation therapy and hormone therapy, sarcopenia is associated with toxicity-related early discontinuation of aET. Further studies should validate these findings in women who did not receive adjuvant radiation therapy. These high-risk patients may be candidates for aggressive symptom management and/or alternative treatment strategies to improve outcomes.
Graur, Alexander; Montesi, Sydney B; Lanuti, Michael; Fintelmann, Florian J
Treating lung cancer in patients with interstitial lung disease: what do we know? Miscellaneous
2023, ISSN: 2072-1439.
@misc{pmid37197553,
title = {Treating lung cancer in patients with interstitial lung disease: what do we know?},
author = {Alexander Graur and Sydney B Montesi and Michael Lanuti and Florian J Fintelmann},
doi = {10.21037/jtd-23-316},
issn = {2072-1439},
year = {2023},
date = {2023-04-01},
journal = {J Thorac Dis},
volume = {15},
number = {4},
pages = {1555--1558},
keywords = {},
pubstate = {published},
tppubtype = {misc}
}
Graur, Alexander; Montesi, Sydney B; Lanuti, Michael; Fintelmann, Florian J
Treating lung cancer in patients with interstitial lung disease: what do we know? Miscellaneous
2023, ISSN: 2072-1439.
@misc{pmid37197553b,
title = {Treating lung cancer in patients with interstitial lung disease: what do we know?},
author = {Alexander Graur and Sydney B Montesi and Michael Lanuti and Florian J Fintelmann},
doi = {10.21037/jtd-23-316},
issn = {2072-1439},
year = {2023},
date = {2023-04-01},
journal = {J Thorac Dis},
volume = {15},
number = {4},
pages = {1555--1558},
keywords = {},
pubstate = {published},
tppubtype = {misc}
}
Graur, Alexander; Montesi, Sydney B; Lanuti, Michael; Fintelmann, Florian J
Treating lung cancer in patients with interstitial lung disease: what do we know? Miscellaneous
2023, ISSN: 2072-1439.
@misc{pmid37197553c,
title = {Treating lung cancer in patients with interstitial lung disease: what do we know?},
author = {Alexander Graur and Sydney B Montesi and Michael Lanuti and Florian J Fintelmann},
doi = {10.21037/jtd-23-316},
issn = {2072-1439},
year = {2023},
date = {2023-04-01},
journal = {J Thorac Dis},
volume = {15},
number = {4},
pages = {1555--1558},
keywords = {},
pubstate = {published},
tppubtype = {misc}
}